Advertisement

Pharmaceutical Research

, Volume 32, Issue 9, pp 3110–3118 | Cite as

Salt Stability – The Effect of pHmax on Salt to Free Base Conversion

  • Yi-Ling Hsieh
  • Jeremy M. Merritt
  • Weili Yu
  • Lynne S. TaylorEmail author
Research Paper

Abstract

Purpose

The aim of this study was to investigate how the disproportionation process can be impacted by the properties of the salt, specifically pHmax.

Methods

Five miconazole salts and four sertraline salts were selected for this study. The extent of conversion was quantified using Raman spectroscopy. A mathematical model was utilized to estimate the theoretical amount of conversion.

Results

A trend was observed that for a given series of salts of a particular basic compound (both sertraline and miconazole are bases), the extent of disproportionation increases as pHmax decreases. Miconazole phosphate monohydrate and sertraline mesylate, although exhibiting significantly different pHmax values (more than 2 units apart), underwent a similar extent of disproportionation, which may be attributed to the lower buffering capacity of sertraline salts.

Conclusion

This work shows that the disproportionation tendency can be influenced by pHmax and buffering capacity and thus highlights the importance of selecting the appropriate salt form during the screening process in order to avoid salt-to-free form conversion.

KEY WORDS

buffering capacity mathematical modelling pHmax salt disproportionation 

Abbreviations

API

Active pharmaceutical ingredient

PXRD

Powder X-ray diffraction

RH

Relative humidity

TGA

Thermogravimetric analysis

TSPd

Tribasic sodium phosphate dodecahydrate

Notes

Acknowledgments

The Dane O’Kildsig Center for Pharmaceutical Processing Research is acknowledged for providing funding for this project. Pfizer Inc is thanked for providing a fellowship for Yi-Ling Hsieh. Sheri L. Shamblin, Kenneth C. Waterman, and Evgenyi Y. Shalaev, are thanked for the helpful discussions. Chris Seadeek is acknowledged for assisting in salt screens.

References

  1. 1.
    Rohrs BR, Thamann TJ, Gao P, Stelzer DJ, Bergren MS, Chao RS. Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrant. Pharm Res. 1999;16(12):1850–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Zannou EA, Ji Q, Joshi YM, Serajuddin ATM. Stabilization of the maleate salt of a basic drug by adjustment of microenvironmental pH in solid dosage form. Int J Pharm. 2007;337(1–2):210–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Williams AC, Cooper VB, Thomas L, Griffith LJ, Petts CR, Booth SW. Evaluation of drug physical form during granulation, tabletting and storage. Int J Pharm. 2004;275(1–2):29–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Unger EF. Weighing benefits and risks – the FDA’s review of prasugrel. N Engl J Med. 2009;361(10):942–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Box KJ, Comer JEA. Using measured pK(a), LogP and solubility to investigate supersaturation and predict BCS class. Curr Drug Metab. 2008;9(9):869–78.PubMedCrossRefGoogle Scholar
  6. 6.
    Hsieh YL, Yu W, Xiang Y, Pan W, Waterman KC, Shalaev EY, et al. Impact of sertraline salt form on the oxidative stability in powder blends. Int J Pharm. 2014;461(1–2):322–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Bogardus JB, Blackwood RK. Solubility of doxycycline in aqueous solution. J Pharm Sci. 1979;68(2):188–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Hsieh Y-L, Taylor LS. Salt stability - effect of particle size, relative humidity, temperature and composition on salt to free base conversion. Pharm Res. 2015;32(2):549–61.Google Scholar
  9. 9.
    Christensen NPA, Rantanen J, Cornett C, Taylor LS. Disproportionation of the calcium salt of atorvastatin in the presence of acidic excipients. Eur J Pharm Biopharm. 2012;82(2):410–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Guerrieri P, Taylor L. Role of salt and excipient properties on disproportionation in the solid-state. Pharm Res. 2009;26(8):2015–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Guerrieri P, Rumondor A, Li T, Taylor L. Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts. AAPS PharmSciTech. 2010;11(3):1212–22.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Ye YK, Stringham RW. Effect of mobile phase acidic additives on enantioselectivity for phenylalanine analogs. J Chromatogr A. 2001;927(1–2):47–52.Google Scholar
  13. 13.
    Smith M. Organic chemistry: an acid–base approach. Boca Raton: CRC Press.Google Scholar
  14. 14.
    Glombitza BW, Oelkrug D, Schmidt PC. Surface-acidity of solid pharmaceutical excipients.1. determination of the surface-acidity. Eur J Pharm Biopharm. 1994;40(5):289–93.Google Scholar
  15. 15.
    Glombitza BW, Schmidt PC. Surface-acidity of solid pharmaceutical excipients.2. effect of the surface-acidity on the decomposition rate of acetylsalicylic-acid. Eur J Pharm Biopharm. 1995;41(2):114–9.Google Scholar
  16. 16.
    Chatterjee K, Shalaev EY, Suryanarayanan R, Govindarajan R. Correlation between chemical reactivity and the hammett acidity function in amorphous solids using inversion of sucrose as a model reaction. J Pharm Sci. 2008;97(1):274–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Govindarajan R, Zinchuk A, Hancock B, Shalaev E, Suryanarayanan R. Ionization states in the microenvironment of solid dosage forms: effect of formulation variables and processing. Pharm Res. 2006;23(10):2454–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Derjarguin BV, Churaev NV. Structure of water in thin layers. Langmuir. 1987;3(5):607–12.CrossRefGoogle Scholar
  19. 19.
    Peters SJ, Ewing GE. Water on salt: an infrared study of adsorbed H2O on NaCl(100) under ambient conditions. J Phys Chem B. 1997;101(50):10880–6.CrossRefGoogle Scholar
  20. 20.
    Peters SJ, Ewing GE. Thin film water on NaCl(100) under ambient conditions: an infrared study. Langmuir. 1997;13(24):6345–8.CrossRefGoogle Scholar
  21. 21.
    Serajuddin ATM, Jarowski CI. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts II: salicylic acid, theophylline, and benzoic acid. J Pharm Sci. 1985;74(2):148–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Urbansky ET, Schock MR. Understanding, deriving, and computing buffer capacity. J Chem Educ. 2000;77(12):1640.CrossRefGoogle Scholar
  23. 23.
    Van Slyke DD, Hastings AB, Heidelberger M, Neill JM. Studies of gas and electrolyte equilibria in the blood. J Biol Chem. 1922;54(2):481–506.Google Scholar
  24. 24.
    John C, Xu W, Lupton L, Harmon P. Formulating weakly basic HCl salts: relative ability of common excipients to induce disproportionation and the unique deleterious effects of magnesium stearate. Pharm Res. 2013;30(6):1628–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Merritt J, Viswanath S, Stephenson G. Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation. Pharm Res. 2013;30(1):203–17.PubMedGoogle Scholar
  26. 26.
    Properties of substance: sodium phosphate dodecahydrate. Available from http://chemister.ru/Database/properties-en.php?dbid=1&id=781.
  27. 27.
    Merck Index. 14th ed. Whitehouse Station: Merck; 1996. p. 7500.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Yi-Ling Hsieh
    • 1
    • 2
  • Jeremy M. Merritt
    • 3
  • Weili Yu
    • 4
  • Lynne S. Taylor
    • 1
    Email author
  1. 1.Department of Industrial and Physical PharmacyPurdue UniversityWest LafayetteUSA
  2. 2.Novartis Pharmaceutical CorporationSan CarlosUSA
  3. 3.Eli Lilly & CoIndianapolisUSA
  4. 4.Pfizer Global Research and DevelopmentGrotonUSA

Personalised recommendations